Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 21,446 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 21,446 shares of Galectin Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $3.65, for a total value of $78,277.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Khurram Jamil also recently made the following trade(s):

• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.90, for a total value of $99,446.10.
• On Friday, January 2nd, Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $54,831.00.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.04, for a total transaction of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The stock was sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Price Performance

Shares of GALT stock traded down $0.43 during trading on Tuesday, reaching $3.45. The company’s stock had a trading volume of 905,529 shares, compared to its average volume of 684,117. Galectin Therapeutics Inc. has a 1-year low of $1.07 and a 1-year high of $7.13. The stock’s 50-day moving average price is $5.34 and its 200 day moving average price is $4.39. The company has a market capitalization of $222.42 million, a price-to-earnings ratio of -5.85 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts anticipate that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on GALT. HC Wainwright lifted their price objective on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Galectin Therapeutics has a consensus rating of “Hold” and a consensus price target of $11.00.

Galectin Therapeutics News Summary

Here are the key news stories impacting Galectin Therapeutics this week:

• Negative Sentiment: CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. CEO Joel Lewis Form 4
• Negative Sentiment: CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. CFO Jack W. Callicutt Form 4
• Negative Sentiment: Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. Khurram Jamil Form 4
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short‑term selling pressure. Pomerantz Investor Alert

Institutional Trading of Galectin Therapeutics

Several hedge funds have recently modified their holdings of GALT. Nuveen LLC purchased a new stake in shares of Galectin Therapeutics during the 1st quarter worth $34,000. Atwood & Palmer Inc. acquired a new position in Galectin Therapeutics during the third quarter worth about $42,000. Archer Investment Corp purchased a new position in Galectin Therapeutics in the third quarter valued at about $47,000. Bank of America Corp DE lifted its position in shares of Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after acquiring an additional 19,316 shares during the period. Finally, Hudson Bay Capital Management LP purchased a new stake in shares of Galectin Therapeutics during the 3rd quarter worth approximately $63,000. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.